US 11,702,400 B2
Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors
Lingyun Wu, Shanghai (CN); Zheming Xiao, Shanghai (CN); Chunyan Jiang, Shanghai (CN); Jian Li, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to MEDSHINE DISCOVERY INC., Jiangsu (CN)
Appl. No. 17/767,104
Filed by MEDSHINE DISCOVERY INC., Jiangsu (CN)
PCT Filed Oct. 16, 2020, PCT No. PCT/CN2020/121388
§ 371(c)(1), (2) Date Apr. 7, 2022,
PCT Pub. No. WO2021/073592, PCT Pub. Date Apr. 22, 2021.
Claims priority of application No. 201910993446.1 (CN), filed on Oct. 18, 2019.
Prior Publication US 2022/0380336 A1, Dec. 1, 2022
Int. Cl. C07D 401/04 (2006.01)
CPC C07D 401/04 (2013.01) [C07B 2200/13 (2013.01)] 13 Claims
 
1. A crystal form A of the hydrochloride having a structure shown in formula (II-1), wherein, the X-ray powder diffraction pattern thereof measured by Cu Kα radiation has characteristic diffraction peaks at the following 2θ angles: 14.77±0.20°, 20.50±0.20°, 22.38±0.20° and 24.15±0.20°;

OG Complex Work Unit Chemistry